Nuvation Bio Inc. (NUVB)

Market Cap	2.93B
Revenue (ttm)	26.75M
Net Income (ttm)	-217.48M
Shares Out	342.83M
EPS (ttm)	-0.64
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,070,699
Open	8.33
Previous Close	8.31
Day's Range	8.15 - 8.70
52-Week Range	1.54 - 8.70
Beta	1.59
Analysts	Strong Buy
Price Target	9.63 (+12.63%)
Earnings Date	Nov 3, 2025

About NUVB

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; and NUV-868, a binding domain 2 bromodomain and ext...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 220
• Stock Exchange: NYSE
• Ticker Symbol: NUVB
• Website: https://www.nuvationbio.com

Analyst Forecast

According to 8 analysts, the average rating for NUVB stock is "Strong Buy." The 12-month stock price target is $9.63, which is an increase of 12.63% from the latest price.

Price Target

$9.63

(12.63% upside)

Analyst Consensus: Strong Buy